Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Longboard Pharmaceuticals (LBPH) just unveiled an announcement.
On August 1, 2024, a company announced encouraging top-line results from a Phase 1 study of their new drug LP659, involving 32 healthy volunteers. The drug was well-tolerated, with no serious adverse events, treatment-related discontinuations, or significant impacts on heart rate, electrocardiograms, or other critical health markers. Additionally, LP659 showed promising signs of efficacy, rapidly reducing lymphocytes in a dose-responsive way. This information is poised to be a focal point in upcoming discussions with investors and analysts.
Find detailed analytics on LBPH stock on TipRanks’ Stock Analysis page.